Navigation Links
FDA Says It Hasn't Decided Whether to Pull Diabetes Drug Avandia Off the Market
Date:2/22/2010

Controversial medicine raises users' heart risk, leaked files suggest, but agency still reviewing data

MONDAY, Feb. 22 (HealthDay News) -- The U.S. Food and Drug Administration on Monday said it was still reviewing documents that examine whether the blockbuster type 2 diabetes drug Avandia raises users' odds for heart attack and heart failure and should be removed from the market.

In an an agency statement, health officials said they are looking at data from a large, long-term clinical study known as RECORD to see if there are possible heart risks with rosiglitazone (Avandia), although they are also reviewing the results of several observational studies on the cardiovascular safety of Avandia.

"These reviews are ongoing, and no new conclusions or recommendations about the use of rosiglitazone in the treatment of type 2 diabetes have been made at this time," the FDA statement said. "Once [the] FDA completes its review of the data from the RECORD study, the agency will present the totality of new and existing cardiovascular safety data on rosiglitazone at a public meeting in July 2010."

In the meantime, the agency said patients should still take Avandia unless their health-care professional tells them to stop.

On Saturday, The New York Times reported on documents from the U.S. Food and Drug Administration that found that if people now taking Avandia switched to a similar medication, Actos, about 500 heart attacks and 300 cases of heart failure would be eliminated each month. And in a report from the Institute for Safe Medication Practice, Avandia was linked to 304 deaths in the third quarter of 2009 alone, the highest for any prescribed drug in that time period, the Times reported.

In one of the FDA documents, dated October 2008, Drs. David Graham and Kate Gelperin -- drug safety officials at the agency -- agreed that "rosiglitazone should be removed from the market."

The
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Undecided Voters Not So Undecided After All
2. Democrat Mike Turner Backs Single-Payer Healthcare; Opponent Feder Undecided
3. Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not
4. Study questions whether Ontarios primary health care reforms serve the sick and poor
5. Test quickly assesses whether Alzheimers drugs are hitting their target
6. N. California Researchers Testing Whether Marijuana Chemical Can Slow Cancer Growth, With Funding by Susan G. Komen for the Cure(R)
7. Cholesterol-lowering drugs may also lower PSA, but whether they cut cancer risk is still not known
8. Whether combat or peacekeeping, PTSD impacts veterans well-being
9. Age alone should not be used to determine whether to treat prostate cancer with hormones
10. New model predicts whether patients will be free of renal cancer 12 years after initial treatment
11. Virtual biopsy can tell whether colon polyp is benign without removal, Mayo researchers say
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... As residents and business owners ... Burns and Carita Weaver, believe in supporting local ... the Southlake Chamber of Commerce, Carroll Independent School ... launched a website for Southlake mayoral candidate Laura ... tool for Hill’s campaign, the website combines images, ...
(Date:3/1/2015)... 2015 Adults who are not legally ... term or universal policies can now use the QuotesPros.com ... life insurance companies for single adults can now be ... http://quotespros.com/life-insurance.html . , The rate plans that nationwide agencies ... to a number of life protection policies. The term, ...
(Date:3/1/2015)... York, NY (PRWEB) March 01, 2015 ... has grown substantially over the past few weeks in ... LLP are actively filing claims, the Firm announces. ... reflects 7,713 cases in the Bergen County proceeding established ... Inc., compared with a few weeks earlier, when 90 ...
(Date:3/1/2015)... Theme and plugin developers from Pixel ... pack for Final Cut Pro X entitled Transccordion. , ... any FCPX editors project.” Said Christiana Austin, CEO of ... needed to easily drag and drop their accordion transition ... different controls over the parameters of this transition bundle ...
(Date:2/28/2015)... Dallas, TX (PRWEB) March 01, 2015 ... is estimated that 10 percent of urban adult population ... some form of heart diseases and 20-30 percent of ... due to heart ailments and coronary vascular diseases (CVD). ... has launched a new market research report titled “Indian ...
Breaking Medicine News(10 mins):Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2Health News:Best Life Insurance Companies for Single Adults Now Searchable at Insurance Website 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3
... (OTCBB:PVCT) announced that it has obtained approval to begin Phase ... III and IV metastatic melanoma, the most aggressive and deadly ... evaluate efficacy of Provecta in a total of 80 subjects. ... into up to 20 tumors in each subject. Additional treatment ...
... 6 Nuvelo, Inc.,(Nasdaq: NUVO ) today ... in September: Bank of America 37th Annual ... PT Dr. Ted W. Love, Chairman and ... Breakout: http://www.veracast.com/webcasts/bas/37th-annual-2007/id89117822.cfm ...
... Purchase Vehicles, HARRISBURG, Pa., Sept. 5 ... people with disabilities will be,better able to get ... in 27,human service transportation providers. The organizations will ... citizens and people with disabilities deserve the same ...
... of two of Pittsburgh,s,finest long term care providers ... within one health care system. Today, the,Sisters of ... Charity announced,that they will integrate Marian Manor Corporation, ... operated by the Sisters of the Holy Spirit, ...
... N.J., Sept. 6 MedQuist Inc.,(Pink Sheets: ... technology and services, announces the re-launch of ... site has been completely redesigned with,assistance from ... Scott Bennett, MedQuist senior vice president of ...
... in 10 Students Suffer Chronic Back Pain Related ... With two weeks to go until the,annual National ... United States are gearing up to help students,"Pack ... by the American,Occupational Therapy Association (AOTA), is set ...
Cached Medicine News:Health News:Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation 2Health News:Governor Rendell Announces $2.1 Million Investment in Small Transit Vehicles 2Health News:Governor Rendell Announces $2.1 Million Investment in Small Transit Vehicles 3Health News:Area Health Care Providers Announce Plans to Integrate Services 2Health News:MedQuist Re-launches New, Improved Web Site 2Health News:Two Weeks Until National School Backpack Awareness Day 2
(Date:2/27/2015)... Feb. 27, 2015  Boston Scientific Corporation (NYSE: ... Barclays 2015 Annual Healthcare Conference on March 10 in ... Dan Brennan , executive vice president and chief financial ... Relations, will participate in a 25-minute question and answer ... approximately 1:05 p.m. ET. Following a 5-minute break, a ...
(Date:2/27/2015)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the fourth quarter and full year ended December ... year for PTC. We are now a growing commercial-stage ... in the rare disease space," stated Stuart W. Peltz, ... proud to bring the first treatment for Duchenne muscular ...
(Date:2/27/2015)... NEWTON, Mass. and JERUSALEM ... privately-held biopharma company developing octreotide capsules, its lead product ... of a $70 million Series E financing round. Participants ... and Sofinnova Ventures, and an undisclosed blue chip public ... F2 Capital, 7 Med Health Ventures, Abingworth and ARCH ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... Vical Incorporated (Nasdaq:,VICL) today reported financial results for the ... of 2007 were $3.1 million, compared with,revenues of $7.3 ... loss for,the second quarter of 2007 was $8.2 million, ... $3.2 million, or $0.11 per share, for the second ...
... Vaccine to be tested with ... ImmuneRegen,s ... owned subsidiary of IR BioSciences Holdings, Inc.,(OTC Bulletin Board: IRBO), ... VaxGen Inc. (Pink Sheets: VXGN.PK). As part,of the agreement, ImmuneRegen ...
Cached Medicine Technology:Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 2Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 3Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 4Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 5Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 6ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc. 2ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc. 3ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc. 4
... Bausch & Lomb PreserVision® AREDS formula ... and mineral supplement clinically proven effective in ... Age Related Eye Disease Study (AREDS). , ... and mineral supplement with the antioxidant vitamins ...
Ocuvite® vitamin and mineral supplements contain 2 mg of Lutein 8 times more than the leading multivitamins. Ocuvite also contains vitamin antioxidants A, C and E, as well as the minerals zinc, ...
HydroEye is an exclusive formulation designed to provide dry eye relief and support the body's natural tear formation. Like all ScienceBased Health formulations, it is produced in softgel form for ma...
Easy-to-use desktop QC data management solution...
Medicine Products: